100.00% -0.7206

Cyclo Therapeutics Inc (CYTH)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Cyclo Therapeutics Inc Stock (CYTH) Company Profile

Cyclo Therapeutics Inc

Healthcare (1174)

386-418-8060

6714 NW 16TH STREET, SUITE B, GAINESVILLE

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CYTH's Discussions on Twitter

Vergleichen Sie CYTH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CYTH Cyclo Therapeutics Inc	0.00	25.21M	1.13M	-20.74M	-18.37M	-0.88
RGC Regencell Bioscience Holdings Ltd	38.01	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	157.17	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.41	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.77	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	16.95	20.17B	16.54B	-1.64B	749.00M	-1.45

Cyclo Therapeutics Inc Aktie (CYTH) Neueste Nachrichten

Finanzdaten der Cyclo Therapeutics Inc-Aktie (CYTH)

Cyclo Therapeutics Inc (CYTH)

Cyclo Therapeutics Inc Stock (CYTH) Company Profile

Vergleichen Sie CYTH mit anderen Aktien

Cyclo Therapeutics Inc Aktie (CYTH) Neueste Nachrichten

Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data - The Manila Times

Major Breakthrough: Phase 3 Trial for Fatal Rare Disease NPC1 Gets Critical DMC Approval to Continue - Stock Titan

Rafael Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2025 - MarketScreener

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results - The Manila Times

Rafael Closes $25 Million Rights Offering - marketscreener.com

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering - The Manila Times

Rafael Holdings Announces Final Results And Closing Of Rights Offering - MarketScreener

Rafael CEO Backs $25M Rights Offering to Fund Critical Phase 3 Rare Disease Drug Trial - Stock Titan

Niemann-Pick Disease Market Insights: Key Trends and Developments Across Different Types of Niemann-Pick Disease | DelveInsight - SINA HONG KONG LIMITED

Niemann-Pick Disease Market Insights: Key Trends and - GlobeNewswire

Niemann-Pick Disease Market Forecast 2024-2031: Emerging - openPR.com

Niemann-Pick Disease Type C Treatment Market Forecast 2025-2034:NORTHEASTNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA

Niemann-Pick Disease Type C Market to Expand Significantly - openPR.com

Zevra Cashes in on First FDA-Approved NPC Treatment with PRV - Genetic Engineering and Biotechnology News

RFL stock touches 52-week low at $1.28 amid market challenges - Investing.com

RFL stock touches 52-week low at $1.28 amid market challenges By Investing.com - Investing.com India

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trap - The Manila Times

Rafael Holdings Rights Offering: $25M Deal Terms Revealed, May 29 Deadline Approaches - Stock Titan

Rafael : to Present at LD Micro Investor Conference - marketscreener.com

SEC Form 424B3 filed by Rafael Holdings Inc. - Quantisnow

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results - ADVFN

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times

Rafael Holdings Launches $25M Rights Offering: Key Dates and Terms Investors Must Know - Stock Titan

Hercules Capital: Q1 Earnings Snapshot - marketscreener.com

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times

Rafael Holdings Secures Future: $25M Rights Offering Powers Critical Phase 3 Drug Launch Plans - Stock Titan

Cyclo Therapeutics (NASDAQ:CYTH) and Genfit (NASDAQ:GNFT) Financial Comparison - Defense World

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role - The Manila Times

Rafael Holdings Strengthens its Focus on the Development of Trappsol Cyclo and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role - marketscreener.com

Rafael Holdings Announces Leadership Transition Following Merger with Cyclo Therapeutics and Full Enrollment of TransportNPC™ Phase 3 Trial for Niemann-Pick Disease Treatment - Nasdaq

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces ... - Bluefield Daily Telegraph

Rafael Holdings Pivots to Breakthrough Rare Disease Drug Development as Leadership Changes - Stock Titan

Form 8-KCurrent report - ADVFN

Contrasting BioNTech (NASDAQ:BNTX) and Cyclo Therapeutics (NASDAQ:CYTH) - Defense World

Rafael Holdings finalizes merger with Cyclo Therapeutics By Investing.com - Investing.com South Africa

Rafael Closes Merger With Cyclo Therapeutics - MarketScreener

Rafael Holdings and Cyclo Therapeutics Merge - citybiz

Rafael Holdings Completes Merger With Cyclo Therapeutics Following Shareholder Approvals - MarketScreener

Cyclo Therapeutics Merges with Rafael Holdings - TipRanks

Rafael Holdings Completes Merger with Cyclo Therapeutics - TipRanks

Rafael Holdings finalizes merger with Cyclo Therapeutics - Investing.com

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals - GlobeNewswire

Major Pharma Merger: Rafael Holdings Gains Phase 3 Rare Disease Asset in Strategic Deal - Stock Titan

Rafael Holdings secures shareholder nod for Cyclo Therapeutics merger By Investing.com - Investing.com Canada

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Rafael Holdings secures shareholder nod for Cyclo Therapeutics merger - Investing.com

Cyclo Therapeutics shareholders approve merger with Rafael Holdings By Investing.com - Investing.com South Africa

Cyclo Therapeutics shareholders approve merger with Rafael Holdings - Investing.com

WILLIAM SHANAHAN Obituary (2025)New York, NYNew York Times - Legacy.com

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

March Madness: Flutter Stock Is a Solid Bet on Sustained Growth - The Globe and Mail

Finanzdaten der Cyclo Therapeutics Inc-Aktie (CYTH)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CYTH